Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Apr 26, 2023; 15(4): 150-164
Published online Apr 26, 2023. doi: 10.4252/wjsc.v15.i4.150
Published online Apr 26, 2023. doi: 10.4252/wjsc.v15.i4.150
Current status and prospects of basic research and clinical application of mesenchymal stem cells in acute respiratory distress syndrome
Tian-Yu Liang, Jing-Quan Liu, Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou 310014, Zhejiang Province, China
Li-Hai Lu, Zi-Hao Zheng, Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Si-Yu Tang, The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China
Kai Shi, Department of Respiratory Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, Zhejiang Province, China
Author contributions: All the authors had full access to all the data of the article, who were responsible for data integrity and accuracy; Liu JQ and Liang TY drafted the manuscript; Tang SY, Zheng ZH and Shi K designed the tables and figures; Lu LH worked on supervision; All authors approved the final version of the manuscript.
Supported by The Youth Fund project of the Natural Science Foundation of Zhejiang Province , No. LQ20H15010 ; and Zhejiang Traditional Chinese Medicine Science and Technology Planning Project , No. 2023ZL575 .
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jing-Quan Liu, MD, Doctor, Emergency and Critical Care Center, Intensive Care Unit, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), No. 158 Shangtang Road, Gongshu District, Hangzhou 310014, Zhejiang Province, China. liujqaticu@163.com
Received: December 20, 2022
Peer-review started: December 20, 2022
First decision: January 6, 2023
Revised: January 20, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 26, 2023
Processing time: 127 Days and 0.1 Hours
Peer-review started: December 20, 2022
First decision: January 6, 2023
Revised: January 20, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: April 26, 2023
Processing time: 127 Days and 0.1 Hours
Core Tip
Core Tip: Acute respiratory disease syndrome (ARDS) is a common disease with high morbidity and mortality. ARDS is characterized by increased alveolar-capillary membrane permeability, influx of protein-rich pulmonary edema fluid, and surfactant dysfunction, resulting in severe hypoxemia. Mesenchymal stem cells (MSCs) have the self-renewal and multilineage differentiation properties, and their immunomodulatory abilities have been implicated in the treatment of disease. Herein, we discuss the pathophysiology of ARDS and recent research surrounding the clinical application of MSCs in the treatment of ARDS.